Responses
Poster Presentation
A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses
Compose a Response to This Article
Other responses
No responses have been published for this article.